Conventional Biotech
• Low vanillin yield - Current yields are much lower than what is required for large-scale production.
• Competition from other pathways - Considerable metabolic engineering is required to direct cellular resources exclusively towards vanillin production by blocking competing pathways.
• Instability of vanillin - Inside the microorganisms' living cells, vanillin can be unstable and readily convert into other compounds instead of accumulating. Developing organisms that prevent this is crucial to stabilizing vanillin production.
• Toxicity issues - At higher concentrations, vanillin is toxic to the organisms that produce it. This counter-productive trait puts an upper limit on achievable yields and requires techniques to address toxicity constraints.
• Regulation of multiple genes - Vanillin biosynthesis requires coordination of multiple enzyme-coding genes. Fine-tuning genetic circuits to adequately regulate such multistep pathways is technically difficult.
• Competition from other pathways - Considerable metabolic engineering is required to direct cellular resources exclusively towards vanillin production by blocking competing pathways.
• Instability of vanillin - Inside the microorganisms' living cells, vanillin can be unstable and readily convert into other compounds instead of accumulating. Developing organisms that prevent this is crucial to stabilizing vanillin production.
• Toxicity issues - At higher concentrations, vanillin is toxic to the organisms that produce it. This counter-productive trait puts an upper limit on achievable yields and requires techniques to address toxicity constraints.
• Regulation of multiple genes - Vanillin biosynthesis requires coordination of multiple enzyme-coding genes. Fine-tuning genetic circuits to adequately regulate such multistep pathways is technically difficult.
It takes 5-6 years from R&D to production!
Zelixir AI x Biotech
• We completed R&D 12x faster than usual.
• We completed the pilot trial in four months instead of two years.
• Our second trial took half the time it normally takes.
• Overall, AI shortened the entire process by 2/3.
• We completed the pilot trial in four months instead of two years.
• Our second trial took half the time it normally takes.
• Overall, AI shortened the entire process by 2/3.